SELLAS LIFE SCIENCES GROUP I (SLS) Fundamental Analysis & Valuation

NASDAQ:SLS • US81642T2096

5.53 USD
+0.25 (+4.73%)
At close: Mar 6, 2026
5.41 USD
-0.12 (-2.17%)
Pre-Market: 3/9/2026, 5:05:07 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SLS. SLS was compared to 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SLS as it has an excellent financial health rating, but there are worries on the profitability. SLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. SLS Profitability Analysis

1.1 Basic Checks

  • In the past year SLS has reported negative net income.
  • SLS had a negative operating cash flow in the past year.
  • SLS had negative earnings in each of the past 5 years.
  • SLS had a negative operating cash flow in each of the past 5 years.
SLS Yearly Net Income VS EBIT VS OCF VS FCFSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of SLS (-50.32%) is comparable to the rest of the industry.
  • SLS has a better Return On Equity (-56.85%) than 61.66% of its industry peers.
Industry RankSector Rank
ROA -50.32%
ROE -56.85%
ROIC N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLS Yearly ROA, ROE, ROICSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • SLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLS Yearly Profit, Operating, Gross MarginsSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. SLS Health Analysis

2.1 Basic Checks

  • SLS has more shares outstanding than it did 1 year ago.
  • SLS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLS Yearly Shares OutstandingSLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SLS Yearly Total Debt VS Total AssetsSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • SLS has an Altman-Z score of 87.38. This indicates that SLS is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 87.38, SLS belongs to the best of the industry, outperforming 98.27% of the companies in the same industry.
  • SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.38
ROIC/WACCN/A
WACCN/A
SLS Yearly LT Debt VS Equity VS FCFSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 8.28 indicates that SLS has no problem at all paying its short term obligations.
  • SLS's Current ratio of 8.28 is fine compared to the rest of the industry. SLS outperforms 74.57% of its industry peers.
  • SLS has a Quick Ratio of 8.28. This indicates that SLS is financially healthy and has no problem in meeting its short term obligations.
  • SLS has a Quick ratio of 8.28. This is in the better half of the industry: SLS outperforms 74.57% of its industry peers.
Industry RankSector Rank
Current Ratio 8.28
Quick Ratio 8.28
SLS Yearly Current Assets VS Current LiabilitesSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SLS Growth Analysis

3.1 Past

  • SLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.42%, which is quite impressive.
EPS 1Y (TTM)59.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.98% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.44%
EPS Next 2Y17.79%
EPS Next 3Y18.48%
EPS Next 5Y38.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLS Yearly Revenue VS EstimatesSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2020 2021 2022 2023 2026 2027 2028 2029 2030 2031 200M 400M 600M
SLS Yearly EPS VS EstimatesSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2K -4K -6K -8K -10K

More info and screens

Find the best growth stocksShow best growing peers

0

4. SLS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SLS. In the last year negative earnings were reported.
  • Also next year SLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLS Price Earnings VS Forward Price EarningsSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLS Per share dataSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SLS's earnings are expected to grow with 18.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.79%
EPS Next 3Y18.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SLS Dividend Analysis

5.1 Amount

  • SLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SLS Fundamentals: All Metrics, Ratios and Statistics

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (3/6/2026, 8:00:02 PM)

Premarket: 5.41 -0.12 (-2.17%)

5.53

+0.25 (+4.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-18
Inst Owners20.84%
Inst Owner Change4.45%
Ins Owners0.48%
Ins Owner Change24.82%
Market Cap941.65M
Revenue(TTM)N/A
Net Income(TTM)-25.94M
Analysts82.86
Price Target6.97 (26.04%)
Short Float %27.22%
Short Ratio4.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.9%
Min EPS beat(2)9.99%
Max EPS beat(2)15.82%
EPS beat(4)4
Avg EPS beat(4)21.5%
Min EPS beat(4)9.99%
Max EPS beat(4)33.99%
EPS beat(8)6
Avg EPS beat(8)-1099.88%
EPS beat(12)7
Avg EPS beat(12)-838.93%
EPS beat(16)8
Avg EPS beat(16)-640.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.14%
EPS NY rev (1m)0%
EPS NY rev (3m)1.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.64
P/tB 21.54
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0
BVpS0.27
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.32%
ROE -56.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.28
Quick Ratio 8.28
Altman-Z 87.38
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y49.44%
EPS Next 2Y17.79%
EPS Next 3Y18.48%
EPS Next 5Y38.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.53%
OCF growth 3YN/A
OCF growth 5YN/A

SELLAS LIFE SCIENCES GROUP I / SLS FAQ

What is the fundamental rating for SLS stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLS.


Can you provide the valuation status for SELLAS LIFE SCIENCES GROUP I?

ChartMill assigns a valuation rating of 0 / 10 to SELLAS LIFE SCIENCES GROUP I (SLS). This can be considered as Overvalued.


How profitable is SELLAS LIFE SCIENCES GROUP I (SLS) stock?

SELLAS LIFE SCIENCES GROUP I (SLS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for SLS stock?

The Earnings per Share (EPS) of SELLAS LIFE SCIENCES GROUP I (SLS) is expected to grow by 49.44% in the next year.